In compliance with the SEBI (Prohibition of insider Trading) (Amendment) Regulations, 2018, Marksans Pharma has informed that the Board of directors of the Company has adopted revised Code of Practices and Procedures For Fair Disclosure of Unpublished Price Sensitive Information effective from April 1, 2019. The said revised code is attached herewith and is also available on the Company's website at www.marksanspharma.com.
The above information is a part of company’s filings submitted to BSE.